MedWorm.com provides a medical RSS filtering service. Over 6000 RSS medical sources are combined and output via different filters. This feed contains the latest items from the 'Asia-Pacific Journal of Clinical Oncology' source. Wed, 08 Feb 2012 08:41:15 +0100 http://www.medworm.com/index.php?rid=5580901&cid=s_31106_6_f&fid=31106&url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1743-7563.2011.01435.x Conclusion:  While there was an increase in number of radiotherapy centers, equipment and human resources available, this was insufficient to comply with international guidelines. An adequate enhancement in radiation oncology infrastructure is needed to cope with the predicted rise in cancer incidence. (Source: Asia-Pacific Journal of Clinical Oncology) Asia-Pacific Journal of Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=5580901 Thu, 12 Jan 2012 05:00:00 +0100 5580901 http://www.medworm.com/index.php?rid=5580900&cid=s_31106_6_f&fid=31106&url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1743-7563.2011.01459.x Conclusion:  Eps8 is frequently expressed in OSCC. The aberrant expression of Eps8 closely correlated with poor survival in patients with OSCC. (Source: Asia-Pacific Journal of Clinical Oncology) Asia-Pacific Journal of Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=5580900 Thu, 12 Jan 2012 05:00:00 +0100 5580900 http://www.medworm.com/index.php?rid=5580899&cid=s_31106_6_f&fid=31106&url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1743-7563.2011.01462.x Conclusion:  Tissue characterization using cMRI may provide a useful tool in defining trastuzumab induced cardiotoxicity. (Source: Asia-Pacific Journal of Clinical Oncology) Asia-Pacific Journal of Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=5580899 Thu, 12 Jan 2012 05:00:00 +0100 5580899 http://www.medworm.com/index.php?rid=5580898&cid=s_31106_6_f&fid=31106&url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1743-7563.2011.01466.x Conclusion:  The high prevalence of HBV biomarkers in ECC strongly supports the notion that HBV infection may be a risk factor for ECC. The high frequency of HBxAg expression suggests its important role in the pathogenesis of bile duct neoplasm. (Source: Asia-Pacific Journal of Clinical Oncology) Asia-Pacific Journal of Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=5580898 Thu, 12 Jan 2012 05:00:00 +0100 5580898 http://www.medworm.com/index.php?rid=5580897&cid=s_31106_6_f&fid=31106&url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1743-7563.2011.01467.x Conclusion:  A first‐line regimen of weekly paclitaxel plus capecitabine is effective and tolerable in Thai MBC patients. (Source: Asia-Pacific Journal of Clinical Oncology) Asia-Pacific Journal of Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=5580897 Thu, 12 Jan 2012 05:00:00 +0100 5580897 http://www.medworm.com/index.php?rid=5580896&cid=s_31106_6_f&fid=31106&url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1743-7563.2011.01486.x Conclusion:  The median OS of our patients is similar to published randomized trials. A CEA response of ≥50% at 3 months and good ECOG were independent predictors of OS of patients with mCRC treated with oxaliplatin‐based chemotherapies. (Source: Asia-Pacific Journal of Clinical Oncology) Asia-Pacific Journal of Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=5580896 Thu, 12 Jan 2012 05:00:00 +0100 5580896 http://www.medworm.com/index.php?rid=5580895&cid=s_31106_6_f&fid=31106&url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1743-7563.2011.01487.x Conclusion:  A rituximab infusion over 90‐min was safe and feasible for participants who seek treatment at ambulatory cancer centre. The new regimen has been adopted as a standard practice with better resource utilization. (Source: Asia-Pacific Journal of Clinical Oncology) Asia-Pacific Journal of Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=5580895 Thu, 12 Jan 2012 05:00:00 +0100 5580895 http://www.medworm.com/index.php?rid=5580894&cid=s_31106_6_f&fid=31106&url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1743-7563.2011.01488.x Conclusion:  A proctocolectomy with ileal pouch anal anastomosis maybe the best choice for FAP patients in China. Surgical expertise, good teamwork and careful long‐term follow up are mandatory. (Source: Asia-Pacific Journal of Clinical Oncology) Asia-Pacific Journal of Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=5580894 Thu, 12 Jan 2012 05:00:00 +0100 5580894 http://www.medworm.com/index.php?rid=5580893&cid=s_31106_6_f&fid=31106&url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1743-7563.2011.01489.x Conclusion:  This regimen of TAC is effective and well‐tolerated and is likely to result in improved outcomes since patients can receive optimal multimodality treatments. (Source: Asia-Pacific Journal of Clinical Oncology) Asia-Pacific Journal of Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=5580893 Thu, 01 Dec 2011 05:00:00 +0100 5580893 http://www.medworm.com/index.php?rid=5486325&cid=s_31106_6_f&fid=31106&url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1743-7563.2011.01505.x (Source: Asia-Pacific Journal of Clinical Oncology) Asia-Pacific Journal of Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=5486325 Thu, 01 Dec 2011 05:00:00 +0100 5486325 http://www.medworm.com/index.php?rid=5486324&cid=s_31106_6_f&fid=31106&url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1743-7563.2011.01441.x (Source: Asia-Pacific Journal of Clinical Oncology) Asia-Pacific Journal of Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=5486324 Thu, 01 Dec 2011 05:00:00 +0100 5486324 http://www.medworm.com/index.php?rid=5486323&cid=s_31106_6_f&fid=31106&url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1743-7563.2011.01434.x We describe the case of a 46‐year‐old patient who presented with a radiologically proven sphenoid wing metastasis. The patient presented with left‐sided exophthalmos while receiving systemic chemotherapy for relapsed high‐risk colorectal cancer. A left sphenoid wing metastasis was proven by a head computed tomography scan. A metastatic spread to the sino‐nasal tract is regarded as a poor prognosis determinant in colorectal cancer and presents a unique set of diagnostic and therapeutic challenges. The compression of noble structures such as the optic nerve holds serious implications in terms of quality of life but there is insufficient evidence clarifying whether radiotherapy or surgery represent the best option for these patients, leaving the therapeutic plan to be decided case b... Asia-Pacific Journal of Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=5486323 Thu, 01 Dec 2011 05:00:00 +0100 5486323 http://www.medworm.com/index.php?rid=5486322&cid=s_31106_6_f&fid=31106&url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1743-7563.2011.01461.x Conclusion:  These results support the notion that endothelial cells play an important role in radiation‐induced lung injury, and may be critical to breakdown of the blood–alveolus barrier and microcirculation dysfunction related to radiation‐induced inflammation and fibrosis. (Source: Asia-Pacific Journal of Clinical Oncology) Asia-Pacific Journal of Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=5486322 Thu, 01 Dec 2011 05:00:00 +0100 5486322 http://www.medworm.com/index.php?rid=5486321&cid=s_31106_6_f&fid=31106&url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1743-7563.2011.01433.x Conclusion:  Notch molecules are useful biomarkers in breast cancer especially for Notch1 and DLL4, and Notch1 is expressed differently in different stages of human breast cancer. (Source: Asia-Pacific Journal of Clinical Oncology) Asia-Pacific Journal of Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=5486321 Thu, 01 Dec 2011 05:00:00 +0100 5486321 http://www.medworm.com/index.php?rid=5486320&cid=s_31106_6_f&fid=31106&url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1743-7563.2011.01463.x Conclusion:  With a cost‐effectiveness threshold of 100,000 Baht in Thailand, carboplatin plus paclitaxel was still not cost‐effective. While the selection of a suitable regimen for individual patients should not rely on drug and hospital costs alone, the overall cost, including the burden on patients, should be taken into consideration. (Source: Asia-Pacific Journal of Clinical Oncology) Asia-Pacific Journal of Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=5486320 Thu, 01 Dec 2011 05:00:00 +0100 5486320 http://www.medworm.com/index.php?rid=5486319&cid=s_31106_6_f&fid=31106&url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1743-7563.2011.01436.x Conclusion:  For patients undergoing annual surveillance mammography at Peter MacCallum Cancer Centre, the transition from film to digital mammography was found to be associated with an increase in both the number of additional investigations performed and in the number of hospital visits. The findings of this study should be considered when conversions from film to digital mammography are planned, specifically in terms of cost allocations and the burden on patient services in radiology and outpatient departments. (Source: Asia-Pacific Journal of Clinical Oncology) Asia-Pacific Journal of Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=5486319 Thu, 01 Dec 2011 05:00:00 +0100 5486319 http://www.medworm.com/index.php?rid=5486318&cid=s_31106_6_f&fid=31106&url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1743-7563.2011.01431.x Conclusion:  Our evaluation demonstrated the eviQ protocol system is generally of high quality. However, we identified a number of areas in which eviQ could improve either its development processes or the means by which these processes are communicated to end‐users. This research represents the first comprehensive evaluation of oncology protocols and paves the way for continued quality assurance research to ensure that these tools meet their objective of facilitating evidence‐based medicine, standardizing treatment and, ultimately, improving patient outcomes. (Source: Asia-Pacific Journal of Clinical Oncology) Asia-Pacific Journal of Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=5486318 Thu, 01 Dec 2011 05:00:00 +0100 5486318 http://www.medworm.com/index.php?rid=5486317&cid=s_31106_6_f&fid=31106&url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1743-7563.2011.01464.x Conclusion:  Among Asian lymphoma patients who manifested at least two risk factors for developing TLS, a single fixed dose of rasburicase at 6 mg is deemed to be effective for rapidly lowering uric acid levels as well as sustaining reduced levels for up to 72 h. (Source: Asia-Pacific Journal of Clinical Oncology) Asia-Pacific Journal of Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=5486317 Thu, 01 Dec 2011 05:00:00 +0100 5486317 http://www.medworm.com/index.php?rid=5486316&cid=s_31106_6_f&fid=31106&url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1743-7563.2011.01432.x Conclusion:  Since previous and the present studies on the chromosomal analysis of CD5+DLBL are also contradictory, more detailed comprehensive genetic analysis appears to be needed to elucidate the biological mechanisms of CD5+DLBL. (Source: Asia-Pacific Journal of Clinical Oncology) Asia-Pacific Journal of Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=5486316 Thu, 01 Dec 2011 05:00:00 +0100 5486316 http://www.medworm.com/index.php?rid=5486315&cid=s_31106_6_f&fid=31106&url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1743-7563.2011.01437.x Conclusion:  POT1 was overexpressed in gastric cancer and may be associated with stomach carcinogenesis and gastric cancer progression. (Source: Asia-Pacific Journal of Clinical Oncology) Asia-Pacific Journal of Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=5486315 Thu, 01 Dec 2011 05:00:00 +0100 5486315 http://www.medworm.com/index.php?rid=5486314&cid=s_31106_6_f&fid=31106&url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1743-7563.2011.01502.x AbstractBackground:  The Australian Institute of Health and Welfare and the Australasian Association of Cancer Registries collaborate every year to provide updated information on cancer occurrences and trends in Australia.Method:  Actual number of cases and deaths is presented together with age‐standardised rates for all cancers combined and selected cancer sites from 1982 to 2007, with projections to 2010. Differences in incidence and mortality rates according to age, Indigenous status and remoteness areas are also provided. In addition, change over time in 5‐year relative survival estimates for those diagnosed with cancer is presented, as is information on the participation in Australia's national screening programs for breast, cervical and bowel cancer. The term ‘cancer’ is ... Asia-Pacific Journal of Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=5486314 Thu, 01 Dec 2011 05:00:00 +0100 5486314 http://www.medworm.com/index.php?rid=5486313&cid=s_31106_6_f&fid=31106&url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1743-7563.2011.01507.x (Source: Asia-Pacific Journal of Clinical Oncology) Asia-Pacific Journal of Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=5486313 Thu, 01 Dec 2011 05:00:00 +0100 5486313 http://www.medworm.com/index.php?rid=5486312&cid=s_31106_6_f&fid=31106&url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1743-7563.2011.01503.x (Source: Asia-Pacific Journal of Clinical Oncology) Asia-Pacific Journal of Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=5486312 Thu, 01 Dec 2011 05:00:00 +0100 5486312 http://www.medworm.com/index.php?rid=5359843&cid=s_31106_6_f&fid=31106&url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1743-7563.2011.01473.x (Source: Asia-Pacific Journal of Clinical Oncology) Asia-Pacific Journal of Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=5359843 Sun, 30 Oct 2011 23:50:38 +0100 5359843 http://www.medworm.com/index.php?rid=5359842&cid=s_31106_6_f&fid=31106&url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1743-7563.2011.01482.x (Source: Asia-Pacific Journal of Clinical Oncology) Asia-Pacific Journal of Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=5359842 Sun, 30 Oct 2011 23:50:36 +0100 5359842 http://www.medworm.com/index.php?rid=5359841&cid=s_31106_6_f&fid=31106&url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1743-7563.2011.01474.x (Source: Asia-Pacific Journal of Clinical Oncology) Asia-Pacific Journal of Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=5359841 Sun, 30 Oct 2011 23:50:35 +0100 5359841 http://www.medworm.com/index.php?rid=5359840&cid=s_31106_6_f&fid=31106&url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1743-7563.2011.01485.x (Source: Asia-Pacific Journal of Clinical Oncology) Asia-Pacific Journal of Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=5359840 Sun, 30 Oct 2011 23:50:33 +0100 5359840 http://www.medworm.com/index.php?rid=5359839&cid=s_31106_6_f&fid=31106&url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1743-7563.2011.01472.x (Source: Asia-Pacific Journal of Clinical Oncology) Asia-Pacific Journal of Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=5359839 Sun, 30 Oct 2011 23:50:32 +0100 5359839 http://www.medworm.com/index.php?rid=5359838&cid=s_31106_6_f&fid=31106&url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1743-7563.2011.01469.x (Source: Asia-Pacific Journal of Clinical Oncology) Asia-Pacific Journal of Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=5359838 Sun, 30 Oct 2011 23:50:30 +0100 5359838 http://www.medworm.com/index.php?rid=5359837&cid=s_31106_6_f&fid=31106&url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1743-7563.2011.01477.x (Source: Asia-Pacific Journal of Clinical Oncology) Asia-Pacific Journal of Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=5359837 Sun, 30 Oct 2011 23:50:29 +0100 5359837 http://www.medworm.com/index.php?rid=5359836&cid=s_31106_6_f&fid=31106&url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1743-7563.2011.01471.x (Source: Asia-Pacific Journal of Clinical Oncology) Asia-Pacific Journal of Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=5359836 Sun, 30 Oct 2011 23:50:27 +0100 5359836 http://www.medworm.com/index.php?rid=5359835&cid=s_31106_6_f&fid=31106&url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1743-7563.2011.01470.x (Source: Asia-Pacific Journal of Clinical Oncology) Asia-Pacific Journal of Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=5359835 Sun, 30 Oct 2011 23:50:26 +0100 5359835 http://www.medworm.com/index.php?rid=5359834&cid=s_31106_6_f&fid=31106&url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1743-7563.2011.01468.x (Source: Asia-Pacific Journal of Clinical Oncology) Asia-Pacific Journal of Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=5359834 Sun, 30 Oct 2011 23:50:24 +0100 5359834 http://www.medworm.com/index.php?rid=5359833&cid=s_31106_6_f&fid=31106&url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1743-7563.2011.01478.x (Source: Asia-Pacific Journal of Clinical Oncology) Asia-Pacific Journal of Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=5359833 Sun, 30 Oct 2011 23:50:22 +0100 5359833 http://www.medworm.com/index.php?rid=5359832&cid=s_31106_6_f&fid=31106&url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1743-7563.2011.01479.x (Source: Asia-Pacific Journal of Clinical Oncology) Asia-Pacific Journal of Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=5359832 Sun, 30 Oct 2011 23:50:21 +0100 5359832 http://www.medworm.com/index.php?rid=5359831&cid=s_31106_6_f&fid=31106&url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1743-7563.2011.01475.x (Source: Asia-Pacific Journal of Clinical Oncology) Asia-Pacific Journal of Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=5359831 Sun, 30 Oct 2011 23:50:19 +0100 5359831 http://www.medworm.com/index.php?rid=5359830&cid=s_31106_6_f&fid=31106&url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1743-7563.2011.01480.x (Source: Asia-Pacific Journal of Clinical Oncology) Asia-Pacific Journal of Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=5359830 Sun, 30 Oct 2011 23:50:17 +0100 5359830 http://www.medworm.com/index.php?rid=5359829&cid=s_31106_6_f&fid=31106&url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1743-7563.2011.01484.x (Source: Asia-Pacific Journal of Clinical Oncology) Asia-Pacific Journal of Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=5359829 Sun, 30 Oct 2011 23:50:16 +0100 5359829 http://www.medworm.com/index.php?rid=5359828&cid=s_31106_6_f&fid=31106&url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1743-7563.2011.01445_2.x (Source: Asia-Pacific Journal of Clinical Oncology) Asia-Pacific Journal of Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=5359828 Sun, 30 Oct 2011 23:50:14 +0100 5359828 http://www.medworm.com/index.php?rid=5359827&cid=s_31106_6_f&fid=31106&url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1743-7563.2011.01445.x (Source: Asia-Pacific Journal of Clinical Oncology) Asia-Pacific Journal of Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=5359827 Sun, 30 Oct 2011 23:50:12 +0100 5359827 http://www.medworm.com/index.php?rid=5359826&cid=s_31106_6_f&fid=31106&url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1743-7563.2011.01476.x (Source: Asia-Pacific Journal of Clinical Oncology) Asia-Pacific Journal of Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=5359826 Sun, 30 Oct 2011 23:50:10 +0100 5359826 http://www.medworm.com/index.php?rid=5359825&cid=s_31106_6_f&fid=31106&url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1743-7563.2011.01481.x (Source: Asia-Pacific Journal of Clinical Oncology) Asia-Pacific Journal of Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=5359825 Sun, 30 Oct 2011 23:50:09 +0100 5359825 http://www.medworm.com/index.php?rid=5359824&cid=s_31106_6_f&fid=31106&url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1743-7563.2011.01444.x (Source: Asia-Pacific Journal of Clinical Oncology) Asia-Pacific Journal of Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=5359824 Sun, 30 Oct 2011 23:50:07 +0100 5359824 http://www.medworm.com/index.php?rid=5359823&cid=s_31106_6_f&fid=31106&url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1743-7563.2011.01483.x (Source: Asia-Pacific Journal of Clinical Oncology) Asia-Pacific Journal of Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=5359823 Sun, 30 Oct 2011 23:50:06 +0100 5359823 http://www.medworm.com/index.php?rid=5359822&cid=s_31106_6_f&fid=31106&url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1743-7563.2011.01443.x (Source: Asia-Pacific Journal of Clinical Oncology) Asia-Pacific Journal of Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=5359822 Sun, 30 Oct 2011 23:50:04 +0100 5359822 http://www.medworm.com/index.php?rid=5359821&cid=s_31106_6_f&fid=31106&url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1743-7563.2011.01442.x (Source: Asia-Pacific Journal of Clinical Oncology) Asia-Pacific Journal of Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=5359821 Sun, 30 Oct 2011 23:50:03 +0100 5359821 http://www.medworm.com/index.php?rid=5175436&cid=s_31106_6_f&fid=31106&url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1743-7563.2011.01410.x (Source: Asia-Pacific Journal of Clinical Oncology) Asia-Pacific Journal of Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=5175436 Tue, 30 Aug 2011 12:42:05 +0100 5175436 http://www.medworm.com/index.php?rid=5175435&cid=s_31106_6_f&fid=31106&url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1743-7563.2011.01440.x (Source: Asia-Pacific Journal of Clinical Oncology) Asia-Pacific Journal of Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=5175435 Tue, 30 Aug 2011 12:42:04 +0100 5175435 http://www.medworm.com/index.php?rid=5175434&cid=s_31106_6_f&fid=31106&url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1743-7563.2011.01429.x (Source: Asia-Pacific Journal of Clinical Oncology) Asia-Pacific Journal of Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=5175434 Tue, 30 Aug 2011 12:42:03 +0100 5175434 http://www.medworm.com/index.php?rid=5175433&cid=s_31106_6_f&fid=31106&url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1743-7563.2011.01427.x (Source: Asia-Pacific Journal of Clinical Oncology) Asia-Pacific Journal of Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=5175433 Tue, 30 Aug 2011 12:42:03 +0100 5175433 http://www.medworm.com/index.php?rid=5175432&cid=s_31106_6_f&fid=31106&url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1743-7563.2011.01408.x Conclusion:  The involvement of the central neck should be a major indication of lymph node biopsy and pathological diagnosis regardless of the imaging findings. In the lateral compartment, hypoechogenicity with loss of hilum, microcalcifications, cystic parts and an index value ≥ 0.51 are indications of a lymph node biopsy to rule out malignancy. (Source: Asia-Pacific Journal of Clinical Oncology) Asia-Pacific Journal of Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=5175432 Tue, 30 Aug 2011 12:42:02 +0100 5175432 http://www.medworm.com/index.php?rid=5175431&cid=s_31106_6_f&fid=31106&url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1743-7563.2011.01424.x Conclusion:  While supporting the value of a collaborative approach to clinical trial communications, the study finding that tissue analysis requires a more emotion‐focused approach highlights a new focus for trial communication and confirms the need for doctors to remain flexible in their consultation style. (Source: Asia-Pacific Journal of Clinical Oncology) Asia-Pacific Journal of Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=5175431 Tue, 30 Aug 2011 12:42:01 +0100 5175431 http://www.medworm.com/index.php?rid=5175430&cid=s_31106_6_f&fid=31106&url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1743-7563.2011.01423.x Conclusion:  Patients with locoregional NET had a favorable long‐term survival after curative resection. Distant metastases, hepatobiliary localization and a poor degree of tumor cell differentiation were poor prognostic factors. Further investigational approaches for treatment of advanced disease are needed. (Source: Asia-Pacific Journal of Clinical Oncology) Asia-Pacific Journal of Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=5175430 Tue, 30 Aug 2011 12:42:00 +0100 5175430 http://www.medworm.com/index.php?rid=5175429&cid=s_31106_6_f&fid=31106&url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1743-7563.2011.01405.x Conclusion:  Despite this is being a small retrospective study, survival figures and toxicity profiles of low dose weekly cisplatin are comparable to historical controls using high‐dose regimens, hence justifying our approach. In addition, radiotherapy interruptions are minimized and cisplatin is easy to administer in outpatient settings. Future three‐arm studies could include this regimen as the basis of treatment combined with targeted therapies. (Source: Asia-Pacific Journal of Clinical Oncology) Asia-Pacific Journal of Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=5175429 Tue, 30 Aug 2011 12:41:59 +0100 5175429 http://www.medworm.com/index.php?rid=5175428&cid=s_31106_6_f&fid=31106&url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1743-7563.2011.01409.x Conclusion:  High values of GFR, by 99mTc DTPA radionuclide measurement, are a common finding in pre‐chemotherapy patients irrespective of age. Carboplatin dosing patterns in this group of patients vary among treating oncologists and a standardized approach is needed. (Source: Asia-Pacific Journal of Clinical Oncology) Asia-Pacific Journal of Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=5175428 Tue, 30 Aug 2011 12:41:58 +0100 5175428 http://www.medworm.com/index.php?rid=5175427&cid=s_31106_6_f&fid=31106&url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1743-7563.2011.01422.x Conclusion:  NT pro‐BNP levels are elevated in a significant proportion of patients with normal LVEF receiving trastuzumab. Troponin I levels are not raised in this group, perhaps reflecting the mechanism of cardiotoxicity. The data provide biochemical evidence of subclinical cardiac strain in women receiving trastuzumab. Results are exploratory and have informed the design of a larger study examining the predictive utility of serial serum NT pro‐BNP levels for TRC in the adjuvant setting. (Source: Asia-Pacific Journal of Clinical Oncology) Asia-Pacific Journal of Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=5175427 Tue, 30 Aug 2011 12:41:57 +0100 5175427 http://www.medworm.com/index.php?rid=5175426&cid=s_31106_6_f&fid=31106&url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1743-7563.2011.01406.x Conclusion:  The optimization of MTX, DDP, DOX and IFO based on Chinese patients' physiology increased the tolerance and efficacy for the treatment of osteosarcoma. (Source: Asia-Pacific Journal of Clinical Oncology) Asia-Pacific Journal of Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=5175426 Tue, 30 Aug 2011 12:41:56 +0100 5175426 http://www.medworm.com/index.php?rid=5175425&cid=s_31106_6_f&fid=31106&url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1743-7563.2011.01425.x Conclusion:  Various clinical approaches have been used to treat patients with recurrent HCC after LT in a clinical setting. More effective strategies and clinical guidelines for recurrent HCC following LT must be established. (Source: Asia-Pacific Journal of Clinical Oncology) Asia-Pacific Journal of Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=5175425 Tue, 30 Aug 2011 12:41:55 +0100 5175425 http://www.medworm.com/index.php?rid=5175424&cid=s_31106_6_f&fid=31106&url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1743-7563.2011.01426.x Conclusion:  Outcomes for LS SCLC have improved with combined chemoradiotherapy, in keeping with worldwide data. The trends may also reflect recent improvements in staging and standardization of treatment. The outcome for ES‐SCLC remains poor. (Source: Asia-Pacific Journal of Clinical Oncology) Asia-Pacific Journal of Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=5175424 Tue, 30 Aug 2011 12:41:54 +0100 5175424 http://www.medworm.com/index.php?rid=5175423&cid=s_31106_6_f&fid=31106&url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1743-7563.2011.01420.x AbstractOver the past three decades there has been a move toward organ preservation protocols in the management of locally advanced mucosal head and neck squamous cell carcinomas (LAHNSCC) with combinations of radiotherapy (RT), chemotherapy and, more recently, biological agents. Current standard chemoradiation strategies have reached the upper limits of toxicity. In addition, the traditional one size fits all approach of grouping patients according to traditional clinicopathological features fails to take into account the vast underlying biological heterogeneity of tumors and their host. A number of recent advances such as highly conformal RT, molecular profiling and targeted agents, and improvements in treatment response assessment have set the scene for a fundamental paradigm shift towa... Asia-Pacific Journal of Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=5175423 Tue, 30 Aug 2011 12:41:53 +0100 5175423 http://www.medworm.com/index.php?rid=5175422&cid=s_31106_6_f&fid=31106&url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1743-7563.2011.01407.x AbstractGastric cancer (GC) constitutes a major cause of cancer deaths worldwide. Recent improvements in both surgical techniques and adjuvant and neoadjuvant radiotherapy and chemotherapy approaches have increased the survival of patients with loco‐regional disease. However most patients with GC have advanced disease either at diagnosis or at follow up. Despite recent advances in the treatment of advanced disease, these patients still have poor outcomes. An emerging understanding of the molecular pathways that characterize cell growth, cell cycle, apoptosis, angiogenesis and invasion has provided novel targets in cancer therapy. In this review we describe the current status of targeted therapies in the treatment of GC. These therapeutic strategies include epidermal growth factor recepto... Asia-Pacific Journal of Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=5175422 Tue, 30 Aug 2011 12:41:52 +0100 5175422 http://www.medworm.com/index.php?rid=5175421&cid=s_31106_6_f&fid=31106&url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1743-7563.2011.01421.x AbstractDespite a survival benefit in the first‐line treatment of castrate‐resistant prostate cancer (CRPC) with docetaxel, the prognosis remains limited. There are increasing options available for patients with CRPC in the second‐line setting, but there is currently little consensus regarding the optimal treatment. There have been numerous phase II and retrospective studies examining second‐line options in CRPC, including retreatment with docetaxel, mitoxantrone, cyclophosphamide and carboplatin, which can be associated with meaningful responses in a significant minority of patients. In 2010 three randomized trials were published or presented which demonstrated a survival benefit in the second‐line setting. These included cabazitaxel compared with mitoxantrone, sipuleucel‐T (i... Asia-Pacific Journal of Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=5175421 Tue, 30 Aug 2011 12:41:51 +0100 5175421 http://www.medworm.com/index.php?rid=5175420&cid=s_31106_6_f&fid=31106&url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1743-7563.2011.01430.x AbstractPoly adenosine diphosphate ribose polymerase (PARP) inhibitors have demonstrated single agent activity in the treatment of patients with recurrent BRCA1‐mutated and BRCA2‐mutated breast and ovarian cancers. They also appear to have a potential role as maintenance therapy following chemotherapy in patients with platinum sensitive recurrent sporadic and BRCA1/2 related high‐grade serous ovarian cancers. The concept of BRCAness raises the possibility that PARP inhibitors may be active in selected patients with homologous recombination (HR) DNA repair‐deficient tumors, even if they do not harbor a BRCA1/2 germline mutation. Further research will be required to identify the subset of patients with sporadic cancers who may benefit from PARP inhibitor therapy. Precise details on t... Asia-Pacific Journal of Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=5175420 Tue, 30 Aug 2011 12:41:50 +0100 5175420 http://www.medworm.com/index.php?rid=5175419&cid=s_31106_6_f&fid=31106&url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1743-7563.2011.01419.x AbstractCarcinoids of the ampulla of Vater are infrequent tumors of which a quarter of cases have been detected in patients with type I neurofibromatosis. This hereditary disease is also associated with gastrointestinal stromal tumors (GIST). However, the coincidence of these three entities together have only been formerly detected in five cases. A 53 year‐old female patient, diagnosed with type I neurofibromatosis, with a malignant carcinoid of ampulla of Vater and multiple gastrointestinal stromal tumors in the duodenum and jejunum, was treated with total pancreatectomy and the excision of her intestinal tumors. Five‐years on, a follow‐up showed the patient to be well, and free from tumor recurrence. The coexistence of an ampullary carcinoid tumor, GIST and neurofibramatosis is ver... Asia-Pacific Journal of Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=5175419 Tue, 30 Aug 2011 12:41:49 +0100 5175419 http://www.medworm.com/index.php?rid=5175418&cid=s_31106_6_f&fid=31106&url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1743-7563.2011.01439.x (Source: Asia-Pacific Journal of Clinical Oncology) Asia-Pacific Journal of Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=5175418 Tue, 30 Aug 2011 12:41:49 +0100 5175418 http://www.medworm.com/index.php?rid=5175417&cid=s_31106_6_f&fid=31106&url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1743-7563.2011.01438.x (Source: Asia-Pacific Journal of Clinical Oncology) Asia-Pacific Journal of Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=5175417 Tue, 30 Aug 2011 12:41:48 +0100 5175417 http://www.medworm.com/index.php?rid=5019975&cid=s_31106_6_f&fid=31106&url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1743-7563.2011.01428.x (Source: Asia-Pacific Journal of Clinical Oncology) Asia-Pacific Journal of Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=5019975 Wed, 13 Jul 2011 14:37:59 +0100 5019975 http://www.medworm.com/index.php?rid=5019974&cid=s_31106_6_f&fid=31106&url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1743-7563.2011.01417.x (Source: Asia-Pacific Journal of Clinical Oncology) Asia-Pacific Journal of Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=5019974 Wed, 13 Jul 2011 14:37:59 +0100 5019974 http://www.medworm.com/index.php?rid=5019973&cid=s_31106_6_f&fid=31106&url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1743-7563.2011.01414.x (Source: Asia-Pacific Journal of Clinical Oncology) Asia-Pacific Journal of Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=5019973 Wed, 13 Jul 2011 14:37:58 +0100 5019973 http://www.medworm.com/index.php?rid=5019972&cid=s_31106_6_f&fid=31106&url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1743-7563.2011.01416.x (Source: Asia-Pacific Journal of Clinical Oncology) Asia-Pacific Journal of Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=5019972 Wed, 13 Jul 2011 14:37:57 +0100 5019972 http://www.medworm.com/index.php?rid=5019971&cid=s_31106_6_f&fid=31106&url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1743-7563.2011.01415.x (Source: Asia-Pacific Journal of Clinical Oncology) Asia-Pacific Journal of Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=5019971 Wed, 13 Jul 2011 14:37:56 +0100 5019971 http://www.medworm.com/index.php?rid=5019970&cid=s_31106_6_f&fid=31106&url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1743-7563.2011.01413.x (Source: Asia-Pacific Journal of Clinical Oncology) Asia-Pacific Journal of Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=5019970 Wed, 13 Jul 2011 14:37:56 +0100 5019970 http://www.medworm.com/index.php?rid=5019969&cid=s_31106_6_f&fid=31106&url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1743-7563.2011.01412_2.x (Source: Asia-Pacific Journal of Clinical Oncology) Asia-Pacific Journal of Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=5019969 Wed, 13 Jul 2011 14:37:55 +0100 5019969 http://www.medworm.com/index.php?rid=5019968&cid=s_31106_6_f&fid=31106&url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1743-7563.2011.01412.x (Source: Asia-Pacific Journal of Clinical Oncology) Asia-Pacific Journal of Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=5019968 Wed, 13 Jul 2011 14:37:55 +0100 5019968 http://www.medworm.com/index.php?rid=5019967&cid=s_31106_6_f&fid=31106&url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1743-7563.2011.01411_11.x (Source: Asia-Pacific Journal of Clinical Oncology) Asia-Pacific Journal of Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=5019967 Wed, 13 Jul 2011 14:37:54 +0100 5019967 http://www.medworm.com/index.php?rid=5019966&cid=s_31106_6_f&fid=31106&url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1743-7563.2011.01411_10.x (Source: Asia-Pacific Journal of Clinical Oncology) Asia-Pacific Journal of Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=5019966 Wed, 13 Jul 2011 14:37:53 +0100 5019966 http://www.medworm.com/index.php?rid=5019965&cid=s_31106_6_f&fid=31106&url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1743-7563.2011.01411_9.x (Source: Asia-Pacific Journal of Clinical Oncology) Asia-Pacific Journal of Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=5019965 Wed, 13 Jul 2011 14:37:53 +0100 5019965 http://www.medworm.com/index.php?rid=5019964&cid=s_31106_6_f&fid=31106&url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1743-7563.2011.01411_8.x (Source: Asia-Pacific Journal of Clinical Oncology) Asia-Pacific Journal of Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=5019964 Wed, 13 Jul 2011 14:37:52 +0100 5019964 http://www.medworm.com/index.php?rid=5019963&cid=s_31106_6_f&fid=31106&url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1743-7563.2011.01411_7.x (Source: Asia-Pacific Journal of Clinical Oncology) Asia-Pacific Journal of Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=5019963 Wed, 13 Jul 2011 14:37:52 +0100 5019963 http://www.medworm.com/index.php?rid=5019962&cid=s_31106_6_f&fid=31106&url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1743-7563.2011.01411_6.x (Source: Asia-Pacific Journal of Clinical Oncology) Asia-Pacific Journal of Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=5019962 Wed, 13 Jul 2011 14:37:51 +0100 5019962 http://www.medworm.com/index.php?rid=5019961&cid=s_31106_6_f&fid=31106&url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1743-7563.2011.01411_5.x (Source: Asia-Pacific Journal of Clinical Oncology) Asia-Pacific Journal of Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=5019961 Wed, 13 Jul 2011 14:37:51 +0100 5019961 http://www.medworm.com/index.php?rid=5019960&cid=s_31106_6_f&fid=31106&url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1743-7563.2011.01411_4.x (Source: Asia-Pacific Journal of Clinical Oncology) Asia-Pacific Journal of Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=5019960 Wed, 13 Jul 2011 14:37:50 +0100 5019960 http://www.medworm.com/index.php?rid=5019959&cid=s_31106_6_f&fid=31106&url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1743-7563.2011.01411_3.x (Source: Asia-Pacific Journal of Clinical Oncology) Asia-Pacific Journal of Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=5019959 Wed, 13 Jul 2011 14:37:49 +0100 5019959 http://www.medworm.com/index.php?rid=5019958&cid=s_31106_6_f&fid=31106&url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1743-7563.2011.01411_2.x (Source: Asia-Pacific Journal of Clinical Oncology) Asia-Pacific Journal of Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=5019958 Wed, 13 Jul 2011 14:37:49 +0100 5019958 http://www.medworm.com/index.php?rid=5019957&cid=s_31106_6_f&fid=31106&url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1743-7563.2011.01411.x (Source: Asia-Pacific Journal of Clinical Oncology) Asia-Pacific Journal of Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=5019957 Wed, 13 Jul 2011 14:37:48 +0100 5019957 http://www.medworm.com/index.php?rid=4853928&cid=s_31106_6_f&fid=31106&url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1743-7563.2011.01390.x Conclusion:  This oxaliplatin and gemcitabine schedule has shown activity in advanced NSCLC with modest toxicity. Neither clinical nor PK outcomes were influenced by the sequencing of these agents, although definite conclusions are limited by small patient numbers. The favorable toxicity profile of this doublet, in light of an encouraging RR, warrants its further investigation in NSCLC. (Source: Asia-Pacific Journal of Clinical Oncology) Asia-Pacific Journal of Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=4853928 Tue, 24 May 2011 14:48:15 +0100 4853928 http://www.medworm.com/index.php?rid=4830626&cid=s_31106_6_f&fid=31106&url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1743-7563.2011.01402.x (Source: Asia-Pacific Journal of Clinical Oncology) Asia-Pacific Journal of Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=4830626 Wed, 18 May 2011 14:36:26 +0100 4830626 http://www.medworm.com/index.php?rid=4830625&cid=s_31106_6_f&fid=31106&url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1743-7563.2011.01403.x (Source: Asia-Pacific Journal of Clinical Oncology) Asia-Pacific Journal of Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=4830625 Wed, 18 May 2011 14:36:26 +0100 4830625 http://www.medworm.com/index.php?rid=4830624&cid=s_31106_6_f&fid=31106&url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1743-7563.2011.01388.x Conclusion:  Zoledronic acid administered every 3 months significantly increased BMD in prostate cancer patients receiving ADT. It had a satisfactory adverse event profile and imposed minimal risk on patients' renal function. (Source: Asia-Pacific Journal of Clinical Oncology) Asia-Pacific Journal of Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=4830624 Wed, 18 May 2011 14:36:24 +0100 4830624 http://www.medworm.com/index.php?rid=4830623&cid=s_31106_6_f&fid=31106&url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1743-7563.2011.01392.x Conclusion:  Knowledge about HPV and the HPV vaccine is generally poor in Thai women. However, the acceptability of the HPV vaccine is good. Knowing about HPV and age under 45 years predict the acceptability of the HPV vaccine. (Source: Asia-Pacific Journal of Clinical Oncology) Asia-Pacific Journal of Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=4830623 Wed, 18 May 2011 14:36:23 +0100 4830623 http://www.medworm.com/index.php?rid=4830622&cid=s_31106_6_f&fid=31106&url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1743-7563.2011.01396.x Conclusion:  A universal HPV vaccination program introduced between the ages of 12–29 is superior to cytology screening in reducing the burden of cervical cancer. However, in the next four decades of post‐vaccination era, optimizing the screening program remains the most important measure for cervical cancer prevention. (Source: Asia-Pacific Journal of Clinical Oncology) Asia-Pacific Journal of Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=4830622 Wed, 18 May 2011 14:36:22 +0100 4830622 http://www.medworm.com/index.php?rid=4830621&cid=s_31106_6_f&fid=31106&url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1743-7563.2011.01391.x Conclusion:  Although total annual breast cancer admission numbers and length of stay did not change significantly, hospitalization for treatment‐related complications was less frequent in 2006. The clinical manifestations of metastatic breast cancer appear to be changing, and in our institution are being managed with broader multidisciplinary care. (Source: Asia-Pacific Journal of Clinical Oncology) Asia-Pacific Journal of Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=4830621 Wed, 18 May 2011 14:36:21 +0100 4830621 http://www.medworm.com/index.php?rid=4830620&cid=s_31106_6_f&fid=31106&url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1743-7563.2011.01393.x Conclusion:  RIT with 131I‐rituximab seems to be effective and tolerable for patients with refractory LGL, although this treatment had modest activity in patients with refractory DLBCL. Further studies are warranted to determine the efficacy of 131I‐rituximab for treating the patients with DLBCL. (Source: Asia-Pacific Journal of Clinical Oncology) Asia-Pacific Journal of Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=4830620 Wed, 18 May 2011 14:36:20 +0100 4830620 http://www.medworm.com/index.php?rid=4830619&cid=s_31106_6_f&fid=31106&url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1743-7563.2011.01385.x Conclusion:  Adjuvant FOLFOX was well tolerated in a Japanese cohort of both stage IIIb and IV CRC patients. (Source: Asia-Pacific Journal of Clinical Oncology) Asia-Pacific Journal of Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=4830619 Wed, 18 May 2011 14:36:19 +0100 4830619 http://www.medworm.com/index.php?rid=4830618&cid=s_31106_6_f&fid=31106&url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1743-7563.2011.01389.x Conclusion:  Legislation is unlikely to be a barrier to the use of ART by cancer patients. The main reasons for limited access to ART may be cost or other factors including time pressure, the lack of a partner and age. Further research in this area is warranted. (Source: Asia-Pacific Journal of Clinical Oncology) Asia-Pacific Journal of Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=4830618 Wed, 18 May 2011 14:36:18 +0100 4830618 http://www.medworm.com/index.php?rid=4830617&cid=s_31106_6_f&fid=31106&url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1743-7563.2011.01394.x This article reviews targeted agents used in solid tumor oncology with an emphasis on clinically relevant details. Overall, the evidence of targeted agents causing surgical complications is limited. The greatest amount of evidence exists for bevacizumab causing perioperative complications, possibly due to its extended half‐life. There are limited data for cetuximab, sorafenib and sunitinib and very little for other solid tumor targeted agents. Our findings suggest that there should be heightened pharmacovigilence around targeted agents with respect to perioperative complications and increased post‐surgical support for patients to aid early detection of postoperative complications until definitive data become available. (Source: Asia-Pacific Journal of Clinical Oncology) Asia-Pacific Journal of Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=4830617 Wed, 18 May 2011 14:36:16 +0100 4830617 http://www.medworm.com/index.php?rid=4830616&cid=s_31106_6_f&fid=31106&url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1743-7563.2011.01395.x Conclusion:  Current results are inconclusive due to study heterogeneity and inadequate analyses but suggest that psychosocial interventions are inexpensive on a per patient basis. Future studies should routinely include preference‐based utility instruments to capture psychological distress in economic evaluation. (Source: Asia-Pacific Journal of Clinical Oncology) Asia-Pacific Journal of Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=4830616 Wed, 18 May 2011 14:36:15 +0100 4830616 http://www.medworm.com/index.php?rid=4830615&cid=s_31106_6_f&fid=31106&url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1743-7563.2011.01386.x (Source: Asia-Pacific Journal of Clinical Oncology) Asia-Pacific Journal of Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=4830615 Wed, 18 May 2011 14:36:13 +0100 4830615 http://www.medworm.com/index.php?rid=4830614&cid=s_31106_6_f&fid=31106&url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1743-7563.2011.01404.x (Source: Asia-Pacific Journal of Clinical Oncology) Asia-Pacific Journal of Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=4830614 Wed, 18 May 2011 14:36:11 +0100 4830614 http://www.medworm.com/index.php?rid=4627462&cid=s_31106_6_f&fid=31106&url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1743-7563.2011.01384.x This article reviews the available evidence for the use of three monoclonal antibodies: one – ipilimumab – pending approval in Australia, and two – panitumubab and cetuximab – that has been recently approved. Ipilimubab is a fully human monoclonal antibody that targets cytotoxic T‐lymphocyte‐associated antigen‐4 to increase the activation of T cells, while panitumumab and cetuximab both target the epidermal growth factor. The clinical effectiveness of these treatments has been demonstrated, and careful biological studies have shown factors that predict for both response and resistance. This review outlines some of these factors. (Source: Asia-Pacific Journal of Clinical Oncology) Asia-Pacific Journal of Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=4627462 Thu, 24 Mar 2011 15:15:07 +0100 4627462 http://www.medworm.com/index.php?rid=4627460&cid=s_31106_6_f&fid=31106&url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1743-7563.2011.01383.x AbstractThere has been much recent attention on immunotherapy for cancer due to the promising results of several randomized phase‐III trials. The management of metastatic melanoma in particular is a significant clinical challenge, and it has long been a desired target of immunotherapies due to evidence of the importance of host immune responses. Cytotoxic T‐lymphocyte‐associated antigen‐4 (CTLA‐4) serves as a negative regulator of immunity. Recent trials administering fully‐human anti‐CTLA‐4 monoclonal antibodies to patients with melanoma have demonstrated survival benefits. However, treatment with anti‐CTLA‐4 antibodies is not without potential toxicities. Autoimmune side‐effects, such as diarrhea, bowel inflammation and dermatitis, were the most commonly reported. T... Asia-Pacific Journal of Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=4627460 Thu, 24 Mar 2011 15:15:07 +0100 4627460 http://www.medworm.com/index.php?rid=4627459&cid=s_31106_6_f&fid=31106&url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1743-7563.2011.01382.x AbstractEffective antitumor responses require communication between antigen‐presenting cells, T‐cell subsets, B cells and natural killer cells. However, tumors have developed a number of mechanisms to avoid detection and elimination by the immune system. This results in a microenvironment that can contribute to the failure of the immune response to the tumor or the prevention of effective immune‐mediated killing. Understanding the barriers to effective tumor immunity allows for the rational design of targeted immunotherapies. The characterization of tumor antigens has led to the development of promising vaccine candidates. Our work has concentrated on the cancer/testis antigen NY‐ESO‐1, which has been an important focus in the development of vaccine‐based therapies against mela... Asia-Pacific Journal of Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=4627459 Thu, 24 Mar 2011 15:15:06 +0100 4627459 http://www.medworm.com/index.php?rid=4627458&cid=s_31106_6_f&fid=31106&url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1743-7563.2011.01381.x AbstractThe association between the immune system and malignancy is at the forefront of research aimed at identifying and developing effective immunotherapies to treat and suppress cancer. Understanding the mechanisms underlying the biology, differentiation and effector functions of key immune cells in the tumor microenvironment is central to this process. The stimulation of T cells results in their activation, triggering the release of cellular mediators, including cytokines and chemokines. The interplay between these components determines the polarization of T cells into phenotypically‐, functionally‐ and transcriptionally‐distinct subsets (e.g. T‐helper [Th] 1, Th2, Th17 and T‐regulatory cells). Given that antigen recognition, costimulation and the cytokine milieu are critical... Asia-Pacific Journal of Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=4627458 Thu, 24 Mar 2011 15:15:05 +0100 4627458 http://www.medworm.com/index.php?rid=4627457&cid=s_31106_6_f&fid=31106&url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1743-7563.2011.01380.x (Source: Asia-Pacific Journal of Clinical Oncology) Asia-Pacific Journal of Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=4627457 Thu, 24 Mar 2011 15:15:04 +0100 4627457 http://www.medworm.com/index.php?rid=4627456&cid=s_31106_6_f&fid=31106&url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1743-7563.2011.01379.x (Source: Asia-Pacific Journal of Clinical Oncology) Asia-Pacific Journal of Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=4627456 Thu, 24 Mar 2011 15:15:04 +0100 4627456 http://www.medworm.com/index.php?rid=4561311&cid=s_31106_6_f&fid=31106&url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1743-7563.2011.01366.x (Source: Asia-Pacific Journal of Clinical Oncology) Asia-Pacific Journal of Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=4561311 Tue, 01 Mar 2011 00:00:00 +0100 4561311 http://www.medworm.com/index.php?rid=4561310&cid=s_31106_6_f&fid=31106&url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1743-7563.2011.01376.x (Source: Asia-Pacific Journal of Clinical Oncology) Asia-Pacific Journal of Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=4561310 Tue, 01 Mar 2011 00:00:00 +0100 4561310 http://www.medworm.com/index.php?rid=4490513&cid=s_31106_6_f&fid=31106&url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1743-7563.2011.01378.x (Source: Asia-Pacific Journal of Clinical Oncology) Asia-Pacific Journal of Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=4490513 Fri, 18 Feb 2011 15:13:54 +0100 4490513 http://www.medworm.com/index.php?rid=4490512&cid=s_31106_6_f&fid=31106&url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1743-7563.2011.01377.x (Source: Asia-Pacific Journal of Clinical Oncology) Asia-Pacific Journal of Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=4490512 Fri, 18 Feb 2011 15:13:53 +0100 4490512 http://www.medworm.com/index.php?rid=4490511&cid=s_31106_6_f&fid=31106&url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1743-7563.2010.01368.x (Source: Asia-Pacific Journal of Clinical Oncology) Asia-Pacific Journal of Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=4490511 Fri, 18 Feb 2011 15:13:47 +0100 4490511 http://www.medworm.com/index.php?rid=4400508&cid=s_31106_6_f&fid=31106&url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1743-7563.2010.01369.x Conclusion:  MDC is not being implemented in line with best practice or applied consistently across Australia. This audit has highlighted gaps in care delivery, despite national recommendations about MDC. Areas being neglected can affect the quality of care provided and may put clinicians at medico‐legal risk. Recommendations to improve uptake and effectiveness of MDC are provided. (Source: Asia-Pacific Journal of Clinical Oncology) Asia-Pacific Journal of Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=4400508 Wed, 26 Jan 2011 00:00:00 +0100 4400508 http://www.medworm.com/index.php?rid=4389747&cid=s_31106_6_f&fid=31106&url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1743-7563.2010.01373.x (Source: Asia-Pacific Journal of Clinical Oncology) Asia-Pacific Journal of Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=4389747 Mon, 24 Jan 2011 00:00:00 +0100 4389747 http://www.medworm.com/index.php?rid=4281973&cid=s_31106_6_f&fid=31106&url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1743-7563.2010.01345.x Conclusion:  These data add to the growing phase II data that bevacizumab‐containing regimens are active in advanced HCC patients. Further evaluation of regimens containing bevacizumab with oxaliplatin and/or doxorubicin may be warranted. (Source: Asia-Pacific Journal of Clinical Oncology) Asia-Pacific Journal of Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=4281973 Wed, 22 Dec 2010 00:00:00 +0100 4281973 http://www.medworm.com/index.php?rid=4281972&cid=s_31106_6_f&fid=31106&url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1743-7563.2010.01353.x AbstractVarious factors have recently prompted a re‐evaluation of the role of non‐anthracycline regimens in early stage breast cancer (ESBC). Since 1990 anthracyclines have been a key component of chemotherapy regimens. However, there is increased understanding of the long‐term, irreversible toxicities associated with these therapies, including cardiac failure and secondary leukemia. The development of the taxanes in the 1990s led to new adjuvant chemotherapy regimens and trials of various combinations in an effort to further increase survival and reduce toxicity. Concerns about cardiac toxicity were reinforced with the emergence of trastuzumab for the treatment of HER2‐positive breast cancer. Trastuzumab alone causes cardiac toxicity and increases the risk of cardiac toxicity when... Asia-Pacific Journal of Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=4281972 Wed, 22 Dec 2010 00:00:00 +0100 4281972 http://www.medworm.com/index.php?rid=4281971&cid=s_31106_6_f&fid=31106&url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1743-7563.2010.01355.x Conclusion:  In Asian patients, pegfilgrastim prophylaxis did not show a therapeutic advantage for preventing neutropenic outcomes compared with filgrastim prophylaxis. (Source: Asia-Pacific Journal of Clinical Oncology) Asia-Pacific Journal of Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=4281971 Wed, 22 Dec 2010 00:00:00 +0100 4281971 http://www.medworm.com/index.php?rid=4281970&cid=s_31106_6_f&fid=31106&url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1743-7563.2010.01363.x Conclusion:  The capecitabine monotherapy had a moderate disease control rate and a tolerable toxicity profile as third‐line or fourth‐line treatment for metastatic CRC patients who were refractory to standard chemotherapy with no further treatment options. (Source: Asia-Pacific Journal of Clinical Oncology) Asia-Pacific Journal of Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=4281970 Wed, 22 Dec 2010 00:00:00 +0100 4281970 http://www.medworm.com/index.php?rid=4478227&cid=s_31106_6_f&fid=31106&url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1743-7563.2010.01370.x Conclusion:  A high prevalence of BCR‐ABL gene fusion was observed that appeared as a poor prognostic factor. Identification of this genetic entity at diagnosis is crucial for understanding the nature of adult ALL and for deciding optimal treatment. (Source: Asia-Pacific Journal of Clinical Oncology) Asia-Pacific Journal of Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=4478227 Wed, 01 Dec 2010 00:00:00 +0100 4478227 http://www.medworm.com/index.php?rid=4400507&cid=s_31106_6_f&fid=31106&url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1743-7563.2010.01371.x Conclusion:  Female gender was the most important factor associated with wanting to work part time. This should be considered when planning the oncology workforce, particularly because an increasing number of oncologists are women. (Source: Asia-Pacific Journal of Clinical Oncology) Asia-Pacific Journal of Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=4400507 Wed, 01 Dec 2010 00:00:00 +0100 4400507 http://www.medworm.com/index.php?rid=4389746&cid=s_31106_6_f&fid=31106&url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1743-7563.2010.01375.x Conclusion:  These decision aids could improve decision making for the surgical treatment of early breast cancer. A prospective randomized, control trial is needed to further evaluate the impact of these decision aids, particularly in the case of nodal surgery. (Source: Asia-Pacific Journal of Clinical Oncology) Asia-Pacific Journal of Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=4389746 Wed, 01 Dec 2010 00:00:00 +0100 4389746 http://www.medworm.com/index.php?rid=4350165&cid=s_31106_6_f&fid=31106&url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1743-7563.2010.01374.x We report two cases of the rare neurological paraneoplastic syndrome, limbic encephalitis, as the initial presentation of small cell lung cancer. The first case responded to treatment of the underlying malignancy, while the second required more acute treatment in the intensive care setting. In this case, initial treatment was with immunosuppression to achieve a degree of stability before the underlying malignancy could be treated. Both cases had significant improvement in neurological function. These cases highlight the importance of directed investigation to try and identify an underlying malignancy in patients in whom a diagnosis of limbic encephalitis is made, and the difficulty in managing such patients. (Source: Asia-Pacific Journal of Clinical Oncology) Asia-Pacific Journal of Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=4350165 Wed, 01 Dec 2010 00:00:00 +0100 4350165 http://www.medworm.com/index.php?rid=4332014&cid=s_31106_6_f&fid=31106&url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1743-7563.2010.01372.x (Source: Asia-Pacific Journal of Clinical Oncology) Asia-Pacific Journal of Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=4332014 Wed, 01 Dec 2010 00:00:00 +0100 4332014 http://www.medworm.com/index.php?rid=4300878&cid=s_31106_6_f&fid=31106&url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1743-7563.2010.01354.x Conclusion:  It is important to consider both pharmacokinetics and pharmacogenetics in optimizing gemcitabine accumulation. This represents a classical interaction between genes and environment and provides support for the consideration of both CDA genotype and infusion duration in development of an individualized dosing strategy. (Source: Asia-Pacific Journal of Clinical Oncology) Asia-Pacific Journal of Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=4300878 Wed, 01 Dec 2010 00:00:00 +0100 4300878 http://www.medworm.com/index.php?rid=4281969&cid=s_31106_6_f&fid=31106&url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1743-7563.2010.01364.x Conclusion:  These data suggest that this assay in these cell lineages has limited usefulness as a predictive screen for the endogenous DNA DSB repair competency of radiosensitive cancer patients' cells but can usefully characterize major cellular DSB repair phenotypes. (Source: Asia-Pacific Journal of Clinical Oncology) Asia-Pacific Journal of Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=4281969 Wed, 01 Dec 2010 00:00:00 +0100 4281969 http://www.medworm.com/index.php?rid=4214651&cid=s_31106_6_f&fid=31106&url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1743-7563.2010.01367.x (Source: Asia-Pacific Journal of Clinical Oncology) Asia-Pacific Journal of Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=4214651 Wed, 01 Dec 2010 00:00:00 +0100 4214651 http://www.medworm.com/index.php?rid=4214650&cid=s_31106_6_f&fid=31106&url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1743-7563.2010.01325.x Conclusion:  The biological behavior of early breast cancer with isolated tumor cells on sentinel node biopsy is similar to both micrometastases and macrometastases, i.e. they behave in a node‐positive fashion. This is an early indication that these patients should be treated with more aggressive adjuvant therapy. (Source: Asia-Pacific Journal of Clinical Oncology) Asia-Pacific Journal of Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=4214650 Wed, 01 Dec 2010 00:00:00 +0100 4214650 http://www.medworm.com/index.php?rid=4214649&cid=s_31106_6_f&fid=31106&url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1743-7563.2010.01344.x Conclusion:  Premature closure of this study limits the interpretation of results. While there was a trend towards reduced subjective acute sensory neuropathy with Ca and Mg, this was not significant. Ca and Mg failed to reduce the rate of cumulative sensory neuropathy and instead increased the rate of abnormal NCS, suggesting a significant difference in perceived sensory and objective neuropathy. (Source: Asia-Pacific Journal of Clinical Oncology) Asia-Pacific Journal of Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=4214649 Wed, 01 Dec 2010 00:00:00 +0100 4214649 http://www.medworm.com/index.php?rid=4214648&cid=s_31106_6_f&fid=31106&url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1743-7563.2010.01362.x (Source: Asia-Pacific Journal of Clinical Oncology) Asia-Pacific Journal of Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=4214648 Wed, 01 Dec 2010 00:00:00 +0100 4214648 http://www.medworm.com/index.php?rid=4214647&cid=s_31106_6_f&fid=31106&url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1743-7563.2010.01361.x (Source: Asia-Pacific Journal of Clinical Oncology) Asia-Pacific Journal of Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=4214647 Wed, 01 Dec 2010 00:00:00 +0100 4214647 http://www.medworm.com/index.php?rid=4214646&cid=s_31106_6_f&fid=31106&url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1743-7563.2010.01365.x (Source: Asia-Pacific Journal of Clinical Oncology) Asia-Pacific Journal of Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=4214646 Wed, 01 Dec 2010 00:00:00 +0100 4214646 http://www.medworm.com/index.php?rid=4135194&cid=s_31106_6_f&fid=31106&url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1743-7563.2010.01327.x We report on two patients who developed cranial nerve palsy due to skull base plasmacytoma. Patient 1, a 55‐year old man with multiple myeloma, developed right sixth cranial nerve palsy during a phase of chemotherapy. He had an intracranial plasmacytoma in the clival region and was treated with 30 Gy whole brain radiotherapy. Patient 2, a 40‐year old man, presented with right third cranial nerve palsy and was detected to have a solitary skull base plasmacytoma. He was treated with radiotherapy followed by thalidomide plus dexamethasone. (Source: Asia-Pacific Journal of Clinical Oncology) Asia-Pacific Journal of Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=4135194 Wed, 03 Nov 2010 00:00:00 +0100 4135194 http://www.medworm.com/index.php?rid=4135193&cid=s_31106_6_f&fid=31106&url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1743-7563.2010.01328.x Conclusion:  KW‐2170 is a very well tolerated chemotherapy agent. It has a relatively low PSA response rate, and did not meet the pre‐specifed criteria for further studies. (Source: Asia-Pacific Journal of Clinical Oncology) Asia-Pacific Journal of Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=4135193 Wed, 03 Nov 2010 00:00:00 +0100 4135193 http://www.medworm.com/index.php?rid=4135192&cid=s_31106_6_f&fid=31106&url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1743-7563.2010.01332.x AbstractBilateral uveal metastases from papillary thyroid carcinoma are extremely rare. A 36‐year‐old woman with a 12‐month history of papillary thyroid carcinoma presented with sudden loss of visual acuity and fields in the left eye. An examination and B‐scan revealed a large, solid choroidal lesion in the left eye causing exudative retinal detachment. A small solid mass was also observed in the right eye fundus. Following left eye enucleation, immunohistopathology confirmed metastatic papillary thyroid carcinoma. The authors report the third known case of bilateral choroidal metastases. (Source: Asia-Pacific Journal of Clinical Oncology) Asia-Pacific Journal of Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=4135192 Wed, 03 Nov 2010 00:00:00 +0100 4135192 http://www.medworm.com/index.php?rid=4135191&cid=s_31106_6_f&fid=31106&url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1743-7563.2010.01340.x Conclusion:  ECSF was associated with a response rate and survival similar to that reported with standard ECF. ECSF may provide an alternative regimen to standard ECF when a continuous ambulatory infusion pump is not feasible or not preferred by the patient. CVC complications are a limitation. (Source: Asia-Pacific Journal of Clinical Oncology) Asia-Pacific Journal of Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=4135191 Wed, 03 Nov 2010 00:00:00 +0100 4135191 http://www.medworm.com/index.php?rid=4135214&cid=s_31106_6_f&fid=31106&url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1743-7563.2010.01352.x (Source: Asia-Pacific Journal of Clinical Oncology) Asia-Pacific Journal of Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=4135214 Mon, 01 Nov 2010 00:00:00 +0100 4135214 http://www.medworm.com/index.php?rid=4135213&cid=s_31106_6_f&fid=31106&url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1743-7563.2010.01357.x (Source: Asia-Pacific Journal of Clinical Oncology) Asia-Pacific Journal of Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=4135213 Mon, 01 Nov 2010 00:00:00 +0100 4135213 http://www.medworm.com/index.php?rid=4135212&cid=s_31106_6_f&fid=31106&url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1743-7563.2010.01351.x (Source: Asia-Pacific Journal of Clinical Oncology) Asia-Pacific Journal of Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=4135212 Mon, 01 Nov 2010 00:00:00 +0100 4135212 http://www.medworm.com/index.php?rid=4135211&cid=s_31106_6_f&fid=31106&url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1743-7563.2010.01350.x (Source: Asia-Pacific Journal of Clinical Oncology) Asia-Pacific Journal of Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=4135211 Mon, 01 Nov 2010 00:00:00 +0100 4135211 http://www.medworm.com/index.php?rid=4135210&cid=s_31106_6_f&fid=31106&url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1743-7563.2010.01349.x (Source: Asia-Pacific Journal of Clinical Oncology) Asia-Pacific Journal of Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=4135210 Mon, 01 Nov 2010 00:00:00 +0100 4135210 http://www.medworm.com/index.php?rid=4135209&cid=s_31106_6_f&fid=31106&url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1743-7563.2010.01358.x (Source: Asia-Pacific Journal of Clinical Oncology) Asia-Pacific Journal of Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=4135209 Mon, 01 Nov 2010 00:00:00 +0100 4135209 http://www.medworm.com/index.php?rid=4135208&cid=s_31106_6_f&fid=31106&url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1743-7563.2010.01359_7.x (Source: Asia-Pacific Journal of Clinical Oncology) Asia-Pacific Journal of Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=4135208 Mon, 01 Nov 2010 00:00:00 +0100 4135208 http://www.medworm.com/index.php?rid=4135207&cid=s_31106_6_f&fid=31106&url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1743-7563.2010.01359_6.x (Source: Asia-Pacific Journal of Clinical Oncology) Asia-Pacific Journal of Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=4135207 Mon, 01 Nov 2010 00:00:00 +0100 4135207 http://www.medworm.com/index.php?rid=4135206&cid=s_31106_6_f&fid=31106&url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1743-7563.2010.01359_5.x (Source: Asia-Pacific Journal of Clinical Oncology) Asia-Pacific Journal of Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=4135206 Mon, 01 Nov 2010 00:00:00 +0100 4135206 http://www.medworm.com/index.php?rid=4135205&cid=s_31106_6_f&fid=31106&url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1743-7563.2010.01359_4.x (Source: Asia-Pacific Journal of Clinical Oncology) Asia-Pacific Journal of Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=4135205 Mon, 01 Nov 2010 00:00:00 +0100 4135205 http://www.medworm.com/index.php?rid=4135204&cid=s_31106_6_f&fid=31106&url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1743-7563.2010.01359_3.x (Source: Asia-Pacific Journal of Clinical Oncology) Asia-Pacific Journal of Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=4135204 Mon, 01 Nov 2010 00:00:00 +0100 4135204 http://www.medworm.com/index.php?rid=4135203&cid=s_31106_6_f&fid=31106&url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1743-7563.2010.01359_2.x (Source: Asia-Pacific Journal of Clinical Oncology) Asia-Pacific Journal of Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=4135203 Mon, 01 Nov 2010 00:00:00 +0100 4135203 http://www.medworm.com/index.php?rid=4135202&cid=s_31106_6_f&fid=31106&url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1743-7563.2010.01359_1.x (Source: Asia-Pacific Journal of Clinical Oncology) Asia-Pacific Journal of Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=4135202 Mon, 01 Nov 2010 00:00:00 +0100 4135202 http://www.medworm.com/index.php?rid=4135201&cid=s_31106_6_f&fid=31106&url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1743-7563.2010.01360.x (Source: Asia-Pacific Journal of Clinical Oncology) Asia-Pacific Journal of Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=4135201 Mon, 01 Nov 2010 00:00:00 +0100 4135201 http://www.medworm.com/index.php?rid=4135200&cid=s_31106_6_f&fid=31106&url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1743-7563.2010.01347.x (Source: Asia-Pacific Journal of Clinical Oncology) Asia-Pacific Journal of Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=4135200 Mon, 01 Nov 2010 00:00:00 +0100 4135200 http://www.medworm.com/index.php?rid=4135199&cid=s_31106_6_f&fid=31106&url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1743-7563.2010.01337.x (Source: Asia-Pacific Journal of Clinical Oncology) Asia-Pacific Journal of Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=4135199 Mon, 01 Nov 2010 00:00:00 +0100 4135199 http://www.medworm.com/index.php?rid=4135198&cid=s_31106_6_f&fid=31106&url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1743-7563.2010.01346.x (Source: Asia-Pacific Journal of Clinical Oncology) Asia-Pacific Journal of Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=4135198 Mon, 01 Nov 2010 00:00:00 +0100 4135198